parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	group enriched in oligodendrocytes (3391 nCPM)	1.00
chemistry Open Targets	a small-molecule pocket	0.60
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	2 Parkinson's papers of 72	0.85
pathways Reactome	3 pathways; mostly other	0.30

No case: the score is under the bar. Receipt 12328

SLC44A1 in oligodendrocytes, braak-0.19 (p 0.630) → +0.56 (p 0.114)receipt 12335
SLC44A1 in dopamine neurons, braak-0.09 (p 0.815) → +0.43 (p 0.243)receipt 12336

receipt 12336: SLC44A1 in dopamine neurons, braak

power: full sample +0.11 (p 0.671, n 18), 95% CI -0.38 to +0.55. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.08 (p 0.748, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.38 (p 0.120, n 18). could be the mix.
skeptic: leave-one-out range -0.01 to +0.25, sign flips 1; without severely affected donors +0.11 (p 0.671, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for SLC44A1 in dopamine neurons.

case closed: nothing better to follow up.

receipt 12335: SLC44A1 in oligodendrocytes, braak

power: full sample +0.09 (p 0.715, n 18), 95% CI -0.39 to +0.54. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.05 (p 0.834, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.27 (p 0.277, n 18). could be the mix.
skeptic: leave-one-out range -0.02 to +0.22, sign flips 2; without severely affected donors +0.09 (p 0.715, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for SLC44A1 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts